Washington Cancer Institute at MedStar Washington Hospital Center — Washington D.C., District of Columbia

Washington Cancer Institute at MedStar Washington Hospital Center is a clinical research site located in Washington D.C., District of Columbia, United States 20010.

Crixeo Health Trust Score: 77/100 (FAIR). This profile has not yet been claimed by the site owner.

Washington Cancer Institute at MedStar Washington Hospital Center has participated in 13 clinical trials with 5 currently active.

Therapeutic areas: HER2-positive Breast Cancer, Advanced Breast Cancer (Female), HER2 Positive Breast Cancer.

Sponsors: Seagen, a wholly owned subsidiary of Pfizer, Pfizer, Georgetown University.

Sponsor Feasibility Report

Trust Score: 77/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Washington Cancer Institute at MedStar Washington Hospital Center?

Washington Cancer Institute at MedStar Washington Hospital Center has a Crixeo Trust Score of 77/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Washington Cancer Institute at MedStar Washington Hospital Center conducted?

Washington Cancer Institute at MedStar Washington Hospital Center has 13 clinical trials on record, with 5 currently active. Their work covers HER2-positive Breast Cancer, Advanced Breast Cancer (Female), HER2 Positive Breast Cancer.

Is Washington Cancer Institute at MedStar Washington Hospital Center accredited by Crixeo Health?

Yes — Washington Cancer Institute at MedStar Washington Hospital Center holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Washington Cancer Institute at MedStar Washington Hospital Center?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.